DSP options rights to Boston Biomedical’s BBI608 for cancer
Executive Summary
Boston Biomedical Inc. (stem cell-based oncology therapies) has granted Dainippon Sumitomo Pharma Co. Ltd. (DSP) an option for certain Japanese and US rights to its Phase I/II compound BBI608 for all cancer indications.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice